Navigation Links
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Date:10/17/2007

rug regimen in a single once-daily pill."

ATRIPLA was developed through a joint venture partnership between Bristol-Myers Squibb Company and Gilead Sciences. The product was approved by the U.S. Food and Drug Administration in July 2006 and has since become the most-prescribed treatment regimen for patients starting HIV therapy in the United States. In Canada, approximately 60,000 people are living with HIV, and around 2,500 new HIV diagnoses are reported each year.

Clinical data support the use of the three-drug regimen contained in ATRIPLA in HIV treatment-naive patients. A randomized, open label, active-controlled, multicenter, non-inferiority study, Study 934, compared a once-daily regimen of Viread, Emtriva and SUSTIVA, the components of ATRIPLA, with twice-daily Combivir(R) (lamivudine/zidovudine) and once-daily SUSTIVA in treatment-naive patients with HIV. Through 48 weeks, 84 percent of patients in the Viread/Emtriva/SUSTIVA group (n=244) compared to 73 percent of patients in the Combivir/SUSTIVA group (n=243) achieved and maintained a viral load of less than 400 copies/mL. This difference largely results from the higher number of discontinuations in the Combivir/SUSTIVA group due to adverse events (9 percent vs. 4 percent in the Viread/Emtriva/SUSTIVA group) and other reasons including loss to follow-up, patient withdrawal, non-compliance and protocol violation (14 percent vs. 10 percent in the Viread/Emtriva/SUSTIVA group).

In addition, 80 percent and 70 percent of patients in the Viread/Emtriva/SUSTIVA group and the Combivir/SUSTIVA group, respectively, achieved and maintained a viral load less than 50 copies/mL through 48 weeks. Selected treatment-emergent adverse events (Grades 2-4) reported in greater than or equal to 5 percent of patients in the Viread/Emtriva/SUSTIVA group through 48 weeks included dizziness, nausea, diarrhea, fatigue, headache and rash.

Important Product Safety Information About ATRIPLA (efavirenz 600 mg/emtr
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
6. Antidepressant Use May Boost Fracture Risk, From Harvard Womens Health Watch
7. FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations, FDA Regulations
8. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
9. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
10. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
11. Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Energy saving powder 10692 1Energy saving powder 10692 2Energy saving powder 10692 3Exploration by explosion 3A Studying the inner realm of living cells 10689 1Eisai Donates More Than 80 Murals to Hospitals Around the United States 61147 1Eisai Donates More Than 80 Murals to Hospitals Around the United States 61147 2Eisai Donates More Than 80 Murals to Hospitals Around the United States 61147 3
...ry(1) in the current issue of The Journal of Infec...egalovirus (CMV) said the vaccine under,developmen...ptimal dose and,regimen tested, "holds promise" ba...ponses in a majority of CMV-seronegative subjects,... to prevent infection and disease. The,commentary ...
...c.,(OTC Bulletin Board: ANPG), reported today that...(ESI) announced that the U.S. Environmental,Protec...dditional claims to,its disinfectant/sanitizer, En...gainst the "superbug" MRSA (scientifically known a... VRE (scientifically known as,Vancomycin Resistant...
Other Medicine Technology:Promise of Vical's CMV Vaccine Noted by Independent Experts 2Promise of Vical's CMV Vaccine Noted by Independent Experts 3Promise of Vical's CMV Vaccine Noted by Independent Experts 4Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant 2Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant 3Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant 4
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
...Turner Construction Company, the nation,s largest ...d to construct a $441 million replacement hospital...P) in Plainsboro Township, N.J. , , The scope of... linear accelerators and related ancillary and sup...
...ing with a female mouse can extend the reproductiv...ccording to a study conducted by Ralph Brinster an... Pennsylvania School of Veterinary Medicine. The ...the spermatogonial stem cells likely occurs throug...
.... 22 Nearly 2,500 dentists, dental,hygienists, de...Carolina are,expected to take part in the sixth an... 6, 2009, in what promises to be among the largest...cs and community colleges across the,state to trea...
...ight into a built-in volume-control system, , ...t a natural earplug: Your ears appear to be able t...rotect your hearing, and a new study provides mor...rom dangerous noise, said study author Paul Fuchs,...
...arly free events offered this Saturday, January 24... history-making celebration where yogis, novices, ...ryone in between join together to stretch mind, bo...classes and workshops are free -- or nearly free. ...
...n recent years, genetic studies have uncovered hun... such as cancer or diabetes, raising the prospect ...formation in an individual,s genome. ,But the vari...This disappointment has led geneticist Barak Cohen...
Other Medicine News:Health News:Turner Selected to Construct Replacement Hospital for University Medical Center at Princeton 2Health News:Living with females extends the reproductive life of the male mouse, says Penn veterinary researcher 2Health News:Living with females extends the reproductive life of the male mouse, says Penn veterinary researcher 3Health News:North Carolina Dentists Team Up To Treat Needy Children 2Health News:How the Ear Protects Your Hearing 2Health News:Yoga Day USA Changes Lives and Builds Community 2Health News:Genetic interactions are the key to understanding complex traits 2Health News:Genetic interactions are the key to understanding complex traits 3
Common Duct Exploration Set: With N-Circle® Nitinol Tipless Stone Extractor
MAMMOTOME® HH (Hand Held): 8 Gauge Probe
...wound support. Especially suitable for instances i... is desired and containment of wound transudate is... 910 has been found to be inert, nonantigenic, and...mesh is prepared from a synthetic absorbable copol...
...ing walls of tissue are in direct contact with a s... valleys and ridges means less tissue remodeling t...Forming Plug design fills more of the defect with ... for faster healing and defect containment.,Only ...
Medicine Products: